Carbohydrate metabolism parameters in angina patients treated with metoprolol and its combination with trimetazidine

Aim. To study the effects of a β-adrenoblocker (β-AB) metoprolol (Mp) and its combination with trimetazidine (Tmd) on glucose tolerance and insulin sensitivity in patients with angina pectoris.
Material and methods. In total, 28 men aged 46-68 years, with Functional Class (FC) II-III stable angina, positive exercise stress test (EST), and no prior β-AB therapy were examined. Individual Mp doses were selected based on the paired EST results. For one month, the Mp dose of 50 or 100 mg/d was administered twice a day; for the next month, participants received Mp and Tmd (70 mg/d). A standard glucose tolerance test (GTT) was performed at baseline and at the end of one-month periods of Mp or Mp + Tmd treatment. Carbohydrate metabolism disturbances were diagnosed according to the WHO criteria (1999). Insulin resistance (IR) was assessed by HOMA2-IR parameter, and tissue insulin sensitivity by ISI0,120 parameter.
Results. After one month of Mp treatment, a decrease in fasting glucose levels was observed (p=0,025). At the same time, the GTT results demonstrated increased glucose levels 2 hours after glucose load, compared to baseline (p=0,049). Tissue insulin sensitivity (ISI0,120) showed some reduction (p=0,14), while the number of patients with impaired glucose tolerance (IGT) increased from 4 to 8 (p=0,006). The levels of fasting and post-load glycemia after one month of the combination therapy with Mp and Tmd were similar to those after the Mp treatment. Insulin levels at 2 hours after glucose load were higher than those observed after the Mp therapy (p=0,045). Compared to baseline, HOMA2-IR values increased, and IDI0,120 values decreased (p=0,036). The IDI0,120 dynamics suggested a reduction in insulin sensitivity for both treatment regimens. IGT was registered in 10 patients.
Conclusion. In angina patients, impaired glucose control was observed as early as 1 month after the start of Mp treatment. This early impairment could be diagnosed by GTT. Although the combination therapy with Mp and Tmd did not prevent this impairment, but provided a greater antiischemic effect and, therefore, was clinically appropriate

1. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with beta-blockers determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007; 100: 1254-62.

2. Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. Q J Med 2006; 99: 431-6.

3. Bartnik M, Rydén L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25:, 1880-90.

4. Bartnik M, Ryden L, Ohrvik J, et al. Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart. Heart 2007; 93: 72-7.

5. Metelitsa VI, Bochkareva EV, Kokurina EV, et al. An individual choice of antianginal drugs by means of paired bicycle ergometry tests in patients with angina. Therap Archive 1992; 9: 35-9. Russian (Метелица В.И., Бочкарева Е.В., Кокурина Е.В. и др. Индивидуальный выбор антиангинальных препаратов с помощью парных ВЭМ-тестов у больных стенокардией. Тер архив 1992; 9: 35-9).

6. Cooper-DeHoff RM, Handberg EM, Mancia G, et al. INVEST revisited: a review of findings from the International VErapamil SR-Trandolapril Study (INVEST). Expert Rev Cardiovasc Ther 2009; 7(11): 1329-40.

7. Szwed H. Clinical benefits of trimetazidine in patients with recurrent angina. Coron Artery Dis 2004; 15(1): 17-21.

8. Cai JS, Peng ZJ. Effect of trimetazidine on insulin resistance in patients with coronary heart disease. Nan fang Yi ke Da Xue Xue Bao 2006; 26(2): 222-3, 226.

9. Monti LD, Setola E, Fragasso G, et al. Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy. Am J physiol Endocrinol Metab 2006; 290: Е 54-9.

10. Kokurina EV, Bochkareva EV, Metelitsa VI, et al. Anti-ischemic efficiency of trimetazidine in a combination with propranolol in patients with stable effort angina. Cardiology 2000; 5: 10-4. Russian (Кокурина Е.В., Бочкарева Е.В., Метелица В.И. Бутина Е.К. Антиишемическая эффективность триметазидина в комбинации с пропранололом у больных стабильной стенокардией напряжения. Кардиология 2000; 5: 10-4).

11. Wallace NM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-95.

12. Geloneze B, Vasques ACJ, Stabe CFC, et al. HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome – Brazilian Metabolic Syndrome Study (BRAMS). Arq Bras Endocrinol Metab 2009; 53(2): 281-7.

13. Qureshi K, Clements RH, Saeed F, Abrams GA. Comparative evaluation of whole body and hepatic insulin resistance using indices from oral glucose tolerance test in morbidly obese subjects with nonalcoholic fatty liver disease. J Obesity, volume 2010, article ID 741521, doi: 10.1155/2010/741521.

14. Gutt M, Davis CL, Spitzer SB, et al. Validation of the insulin sensitivity index (ISI0,120) comparison with other measures. Diab Res Clin Pract 2000; 47: 177-84.

15. Cooper-Dehoff R, Cohen JD, Bakris GL, et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the International VerapamilTrandolapril Study [INVEST]). Am J Cardiol 2006; 98(7): 890-4 Description of the cohort that developed diabetes during participation in INVEST and predictors of diabetes development.

16. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-9.

17. Almgren T, Wilhelmsen L, Samuelsson J, et al. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens 2007; 25: 1311-7.

18. Liu J, Grundy SM, Wang W, et al. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes and metabolic syndrome. Am Heart J 2007; 153: 552-8.

19. Jacob S, Rett K, Wickimayr M, et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvediolmetoprolol study. J Hypertens 1996; 14(4): 489-94.

20. Poirier L, Cleroux J, Nadeau A, Lacourciere Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 2001; 19(8): 1429-35.

21. Bakris GI, Fonseca V, Katholi RE, et al. Metabolic effects of carvediol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. A Randomized Controlled Trial. JAMA 2004; 292(18): 2227-36.

22. Fonseca V, Bakris GL, Bell DS, at al. Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabet Med 2007; 24(7): 759-63.

23. Micossi P, Pollavini G, Raggi U, et al. Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus. Horm Metab Res 1984; 16(2): 59-63.

24. Olsson G, Rehnqvist N. Effects of chronic metoprolol treatment on glucose tolerance after myocardial infarction. Int J Clin Pharmacol 1987; 33(3): 311-3.

25. Hakamaki T, Lehtonen A. Metabolic effects of spirapril and atenolol: results from a randomized, long-term study. Int J Clin Pharmacol Ther 1997; 35(6): 227-30.

26. Ribeiro LW, Ribeiro JP, Stein R, et al. Trimetazidine added to combined hemodynamic anitianginal therapy in patients with type 2 diabetes: a randomized crossover trial. Am Heart J 2007; 154(1): 78.e1-7.

27. Fragasso G, Piatti PM, Monti L, et al. Short-and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyoparthy. Am Heart J 2003; 146(5): Е18.

28. Vardeny O, Zebrack J, Gilbert EM. Effects of beta-blocker titration on glucose homeostasis in heart failure. J Pharm Technol 2009; 25(2): 71-8.

29. Bhadada SV, Goyal RK. Comparative evaluation of atenolol and metoprolol on cardiovascular complications associated with streptozotocin-induced diabetic rats. Can J Physiol Pharmacol 2007; 85(8): 831-6.